JA
VRTX icon

JOYN Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

JOYN Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-260
Closed -$43K – 1378
2018
Q4 		$43K Buy
260
+104
+67% +$18K 0.01% 398
2018
Q3 		$30K Buy
156
+24
+18% +$4.27K 0.01% 551
2018
Q2 		$22K Buy
132
+116
+725% +$18K ﹤0.01% 653
2018
Q1 		$3K Buy
+16
New +$2.61K ﹤0.01% 1006

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JOYN Advisors's VRTX Position: Q1 2019 in Review

JOYN Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 260 shares — an estimated $43K sold.

JOYN Advisors first reported a position in VRTX in Q1 2018 and held it in 4 quarters. The position peaked at $43K in Q4 2018. 736 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

  • JOYN Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • JOYN Advisors sold 260 Vertex Pharmaceuticals shares in Q1 2019, an estimated $43K.
  • JOYN Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • JOYN Advisors's Vertex Pharmaceuticals position peaked at $43K in Q4 2018.
  • 736 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.